FDA Plans eMDR System Updates

The U.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH) plans to update the FDA’s electronic medical device reporting (eMDR) system to reflect updates to the FDA Form 3500A and other system enhancements. The FDA Form 3500A is...

FDA Clears GE Healthcare’s Deep Learning-Based MR Image Reconstruction

GE Healthcare has announced U.S. FDA 510(k) clearance of AIR Recon DL. “This pioneering technology, using a deep learning-based neural network, improves the patient experience through shorter scan times while also increasing diagnostic confidence with better image...

GlobalData: Impact of COVID-19 on diagnostic imaging not as severe compared to other areas

The impact of COVID-19 on diagnostic imaging (DI) procedures will not be as severe compared to other therapy areas, such as aesthetics and dental, since only 38.7% of these procedures are elective and expected to drop due to the COVID-19 pandemic, according to...

FDA Approves Cerianna

PETNET Solutions Inc., a Siemens Healthineers company, and Zionexa USA, a wholly owned subsidiary of Zionexa SAS, have announced that the Food and Drug Administration (FDA) has approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna...

Varian-equipped New York Proton Therapy Center Treats First Patients

Varian ProBeam® proton therapy system

PALO ALTO, Calif., Sept. 10, 2019 /PRNewswire/ — The New York Proton Center (NYPC) has treated its first proton therapy cancer patients. Equipped with the Varian ProBeam® proton therapy system, NYPC is New York State’s first proton therapy facility and is a collaboration between Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System.

NYPC is expected to treat 1,400 patients annually, including most children in New York City with solid tumors, delivering the most advanced form of cancer radiation treatment currently available. Before NYPC was opened, proton therapy patients in the New York Metro area were referred to out-of-state facilities.

“We are thrilled to be delivering the highest standard of treatment possible and ensuring our patients – many of them children – are receiving this advanced oncology therapy without having to travel out of the state,” said Dr. Charles B. Simone,II, FACRO, chief medical officer at the New York Proton Center. “With the state-of-the-art Varian ProBeam system, we know that our experienced team of proton therapy experts are able to provide patients with the most advanced radiation treatment modality possible.”

Proton therapy uses protons, accelerated to about two-thirds the speed of light, or more than 100,000 miles per second, to destroy cancer cells, while minimizing exposure to nearby healthy tissues. NYPC will treat pediatric and adult patients with a wide variety of conditions, including brain and spine tumors, head and neck tumors, breast cancer, lung and other thoracic cancers, gastrointestinal cancers, sarcomas, gynecologic cancers, prostate cancer, lymphomas and recurrence cancers.

“Seeing our collaboration with long-term strategic partners in radiation oncology at New York Proton Center come to fruition is a very proud moment for Varian,” said Kolleen Kennedy, president, Proton Solutions and chief growth officer at Varian. “This means the most advanced cancer care for patients in the greater New York area, and we are excited to build upon this strong foundation as we partner to deliver on the promise of a world without fear of cancer.”



Submit a Comment

Your email address will not be published. Required fields are marked *